SCHEMBL5543343

SCHEMBL5543343

O=[C]OCCCCCCc1cccc(OCc2ccccc2)c1

nearest known ligand 0.61

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.61
CYP4F2 P78329 1/20 0.55
CYP4A11 Q02928 1/20 0.55
BCHE P06276 5/20 0.51
NR4A2 P43354 1/20 0.50
FFAR1 O14842 1/20 0.47
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
MAOB P27338 4/20 0.47
MAOA P21397 1/20 0.47
CYSLTR2 Q9NS75 1/20 0.46
CYSLTR1 Q9Y271 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542749 1.00 MGLL (0.61) MGLLCYP4F2CYP4A11BCHENR4A2
SCHEMBL5539960 0.99 MGLL (0.59) MGLLCYP4F2CYP4A11BCHENR4A2
SCHEMBL5536626 0.94 CYP4F2 (0.57) MGLLCYP4F2CYP4A11BCHENR4A2
SCHEMBL5544329 0.90 MGLL (0.49) MGLLFFAR1PPARGPPARAMAOB
SCHEMBL5536013 0.89 CYP4F2 (0.60) MGLLCYP4F2CYP4A11BCHENR4A2
SCHEMBL5543685 0.86 MGLL (0.59) MGLLBCHEFFAR1
SCHEMBL5543651 0.86 MGLL (0.59) MGLLBCHEFFAR1
SCHEMBL5543700 0.85 LTA4H (0.59) MGLLBCHEFFAR1
SCHEMBL5543434 0.83 FFAR1 (0.49) MGLLCYP4F2CYP4A11BCHEFFAR1
SCHEMBL5543354 0.81 MGLL (0.61) MGLLCYP4F2CYP4A11BCHENR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MGLL 4717/4885CYP4F2 954/4885CYP4A11 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.